A meta-analysis examined the net impact of GLP-1 agonists on glycemic control, weight, and insulin dose in seven randomized controlled trials in 206 adult subjects with type 1 diabetes also treated with insulin over study durations of 3–15 months (124). The gene discussed is GLP1R; the disease is type 1 diabetes mellitus.